CD BioGlyco has developed and optimized a series of research platforms related to glycobiology. Our first-class technology platform and experienced scientists provide customers with high-precision, high-efficiency, high-throughput, and cost-effective services.
All organisms are composed of four basic substances: nucleic acids, proteins, lipids, and glycans. New research areas such as genomics, proteomics, lipidomics, and metabolomics have appeared that correspond to each of the substances. In the post-genomic era, people have found that the number of proteins encoded in the human genome is between 20,000 and 25,000, but the entire proteome contains more than a million proteins. One of the reasons for this difference is the post-translational modifications of protein that increase the complexity of the proteome. Among them, glycosylation is particularly important.
Glycobiology is defined as the study of the structure, biosynthesis, biological functions of glycans and saccharides conjugates (including glycoproteins, glycolipids, proteoglycans, etc.), as well as protein-glycan interactions. Glycogenomics, glycoproteomics, glycomics, and glycoinformatics help us better understand the various cellular events involved in saccharides and the role of glycans in diseases. In the production of biological agents, glycans also affect the therapeutic properties of protein drugs and their immune responses.
At present, CD BioGlyco has provided a large number of advanced analysis techniques and data analysis tools for glycobiology research. Glyco™ synthesis platform helps to synthesize a variety of glycoconjugates. Glycomics results are combined with other "omics data sets" to gain a deeper understanding and insight into the nature of glycosylation in complex cellular processes. Glycoproteomics platform is used to identify, classify, quantify, and characterize glycoproteins. The glycobiology microarray platform is widely used to analyze the entire glycogen group and glycosylase under pathological conditions. Glyco™ vaccine development helps accelerate vaccine development and preclinical research. Glycoengineering platform is important strategies for improving the safety, consistency, and reduced immunogenicity of biological drugs.
CD BioGlyco is a global biotechnology company that has accomplished a number of successful glycobiology projects. Our technology platform is constantly updated to meet the latest needs of our global customers. Our only goal is to provide high-quality services while saving time, effort, and cost for customers. If you are interested in our services, please contact us for more detailed information.
References:
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
